Table A1.
Graded prognostic assessment (GPA) index of patients with newly diagnosed lung adenocarcinoma with brain metastases.
| Version | Factors | Score | ||
|---|---|---|---|---|
| 0 | 0.5 | 1 | ||
| 2010 | KPS | ≤60 | 70–80 | 90–100 |
| Age | >60 | 50–60 | <50 | |
| Number of BM | ≥4 | 2–3 | 1 | |
| ECM | Present | Absent | ||
| 2017 | KPS | ≤70 | 80 | 90–100 |
| Age | ≥70 | <70 | ||
| Number of BM | ≥5 | 1–4 | ||
| ECM | Present | Absent | ||
| EGFR and ALK | Both negative or unknown | EGFR- or ALK-positive | ||
| 2022 | KPS | ≤70 | 80 | 90–100 |
| Age | ≥70 | <70 | ||
| Number of BM | ≥5 | 1–4 | ||
| ECM | Present | Absent | ||
| EGFR and ALK | Both negative or unknown | EGFR- or ALK-positive | ||
| PD–L1 | Negative or unknown | Positive | ||
Abbreviations: ALK, anaplastic lymphoma kinase; BM, brain metastasis; ECM, extracranial metastasis; EGFR, epidermal growth factor receptor; KPS, Karnofsky performance status; PD-L1, programmed death ligand 1.